NASDAQ:SPTX Seaport Therapeutics (SPTX) Stock Price, News & Analysis $21.43 +0.78 (+3.78%) As of 08/4/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Seaport Therapeutics Stock (NASDAQ:SPTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Seaport Therapeutics alerts:Sign Up Key Stats Today's Range$20.34▼$21.8650-Day Range$16.20▼$22.5252-Week Range$14.85▼$23.00Volume89,902 shsAverage Volume233,916 shsMarket Capitalization$1.15 billionP/E RatioN/ADividend YieldN/APrice Target$38.40Consensus RatingHold Company Overview Read More Seaport Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreSPTX MarketRank™: Seaport Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 290th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingSeaport Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 5 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialSeaport Therapeutics has a consensus price target of $38.40, representing about 79.2% upside from its current price of $21.43.Amount of Analyst CoverageSeaport Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Seaport Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Seaport Therapeutics is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seaport Therapeutics is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.70% of the float of Seaport Therapeutics has been sold short.Short Interest Ratio / Days to CoverSeaport Therapeutics has a short interest ratio ("days to cover") of 12.28, which indicates bearish sentiment.Change versus previous monthShort interest in Seaport Therapeutics has recently decreased by 28.75%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSeaport Therapeutics does not currently pay a dividend.Dividend GrowthSeaport Therapeutics does not have a long track record of dividend growth. News and Social Media1.4 / 5News Sentiment-0.68 News SentimentSeaport Therapeutics has a news sentiment score of -0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Seaport Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Seaport Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.9 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $235,820.00 in company stock, which represents 0.0206% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Seaport Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $235,820.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsSeaport Therapeutics has minimal institutional ownership at this time.Read more about Seaport Therapeutics' insider trading history. Receive SPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seaport Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPTX Stock News HeadlinesSeaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical ProgressAugust 3 at 7:00 AM | businesswire.comSeaport Therapeutics (SPTX) Stock Forecast & Price TargetJuly 19, 2026 | investing.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.August 5 at 1:00 AM | Banyan Hill Publishing (Ad)Seaport Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:SPTXJuly 17, 2026 | benzinga.comSeaport Therapeutics, Inc. (SPTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comPureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgoâ„¢ in Healthy VolunteersJune 9, 2026 | businesswire.comSeaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical ProgressJune 8, 2026 | businesswire.comSeaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy VolunteersJune 8, 2026 | businesswire.comSee More Headlines SPTX Stock Analysis - Frequently Asked Questions How have SPTX shares performed this year? Seaport Therapeutics' stock was trading at $19.84 on April 30, 2026. Since then, SPTX stock has increased by 8.0% and is now trading at $21.43. How were Seaport Therapeutics' earnings last quarter? Seaport Therapeutics, Inc. (NASDAQ:SPTX) released its quarterly earnings data on Monday, August, 3rd. The company reported ($1.78) earnings per share for the quarter, missing the consensus estimate of ($0.71) by $1.07. When did Seaport Therapeutics IPO? Seaport Therapeutics (SPTX) raised $241 million in an initial public offering on Friday, May 1st 2026. The company issued 14,160,000 shares at a price of $16.00-$18.00 per share. When does the company's lock-up period expire? Seaport Therapeutics's lock-up period expires on Wednesday, October 28th. Seaport Therapeutics had issued 14,160,000 shares in its initial public offering on May 1st. The total size of the offering was $254,880,000 based on an initial share price of $18.00. After the expiration of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company. How do I buy shares of Seaport Therapeutics? Shares of SPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/03/2026Today8/05/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SPTX CIK2042347 WebN/A PhoneN/AFaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Seaport Therapeutics$38.40 High Price Target$50.00 Low Price Target$30.00 Potential Upside/Downside+79.2%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares53,531,000Free FloatN/AMarket Cap$1.15 billion OptionableN/A BetaN/A 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:SPTX) was last updated on 8/5/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seaport Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seaport Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.